Gold DT - Search Results

1

Compliance and persistence with osteoporosis therapies.

Silverman SL, Gold DT. Silverman SL, et al. Among authors: gold dt. Curr Rheumatol Rep. 2008 Apr;10(2):118-22. doi: 10.1007/s11926-008-0021-x. Curr Rheumatol Rep. 2008. PMID: 18460266 Review.

2

Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis.

Cramer JA, Silverman SL, Gold DT. Cramer JA, et al. Among authors: gold dt. Curr Med Res Opin. 2007 Oct;23(10):2369-77. doi: 10.1185/030079907X226311. Curr Med Res Opin. 2007. PMID: 17711617

3

Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies.

Silverman SL, Gold DT, Cramer JA. Silverman SL, et al. Among authors: gold dt. South Med J. 2007 Dec;100(12):1214-8. doi: 10.1097/SMJ.0b013e31815a9685. South Med J. 2007. PMID: 18090964 Review.

4

Compliance and persistence with osteoporosis medications: a critical review of the literature.

Silverman S, Gold DT. Silverman S, et al. Among authors: gold dt. Rev Endocr Metab Disord. 2010 Dec;11(4):275-80. doi: 10.1007/s11154-010-9138-0. Rev Endocr Metab Disord. 2010. PMID: 20443140 Free PMC article. Review.

5

Medication Decision-making in Osteoporosis: Can We Explain Why Patients Do Not Take Their Osteoporosis Medications?

Silverman S, Gold DT. Silverman S, et al. Among authors: gold dt. Curr Osteoporos Rep. 2018 Dec;16(6):772-774. doi: 10.1007/s11914-018-0494-0. Curr Osteoporos Rep. 2018. PMID: 30374627 Review.

6

A Qualitative Study to Assess US Patient Preferences between new Transdermal System and Injectable Anabolic Therapies for Osteoporosis Treatment.

Beaudart C, Silverman S, Gold DT, Williams SA, Weiss R, Hiligsmann M. Beaudart C, et al. Among authors: gold dt. Arch Osteoporos. 2022 Apr 4;17(1):57. doi: 10.1007/s11657-022-01075-z. Arch Osteoporos. 2022. PMID: 35378644 Free PMC article.

7

Review of adherence to medications for the treatment of osteoporosis.

Gold DT, Silverman S. Gold DT, et al. Curr Osteoporos Rep. 2006 Mar;4(1):21-7. doi: 10.1007/s11914-006-0011-8. Curr Osteoporos Rep. 2006. PMID: 16527004 Review.

8

Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis.

Silverman S, Calderon A, Kaw K, Childers TB, Stafford BA, Brynildsen W, Focil A, Koenig M, Gold DT. Silverman S, et al. Among authors: gold dt. Osteoporos Int. 2013 Jul;24(7):2067-77. doi: 10.1007/s00198-012-2241-1. Epub 2012 Dec 18. Osteoporos Int. 2013. PMID: 23247328

9

Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.

Silverman SL, Siris E, Kendler DL, Belazi D, Brown JP, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Ferreira I, Balasubramanian A, Dakin P, Ho P, Siddhanti S, Stolshek B, Recknor C. Silverman SL, et al. Among authors: gold dt. Osteoporos Int. 2015 Jan;26(1):361-72. doi: 10.1007/s00198-014-2871-6. Epub 2014 Sep 19. Osteoporos Int. 2015. PMID: 25236877 Free PMC article.

10

Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.

Silverman SL, Siris E, Belazi D, Recknor C, Papaioannou A, Brown JP, Gold DT, Lewiecki EM, Quinn G, Balasubramanian A, Yue S, Stolshek B, Kendler DL. Silverman SL, et al. Among authors: gold dt. Arch Osteoporos. 2018 Aug 7;13(1):85. doi: 10.1007/s11657-018-0491-z. Arch Osteoporos. 2018. PMID: 30088189 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

105 results

Search Page

Filters